3.67
Altimmune Inc (ALT) 最新ニュース
Developing predictive dashboards with Altimmune Inc. data2025 Price Momentum & AI Based Trade Execution Alerts - Newser
Will Altimmune Inc. see short term momentumJuly 2025 Sector Moves & Stepwise Entry/Exit Trade Alerts - Newser
Altimmune Inc. stock prediction for this weekChart Signals & Precise Entry and Exit Recommendations - Newser
Altimmune: Is There Still Hope For Pemvidutide? I Believe There Is (Upgrade) (NASDAQ:ALT) - Seeking Alpha
Altimmune, Inc. Sued for Securities Law Violations – - GlobeNewswire
Altimmune (ALT) Stock Rises on FDA's Acceptance of Surrogate Endpoint - GuruFocus
Will Altimmune Inc. price bounce be sustainableBond Market & Consistent Profit Trade Alerts - Newser
ALT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
ALT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Altimmune, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - GlobeNewswire Inc.
FDA accepts lenient MASH trial requirement (VKTX:NASDAQ) - Seeking Alpha
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune - PR Newswire
Using Python tools to backtest Altimmune Inc. strategiesPortfolio Risk Summary & Growth Focused Entry Point Reports - Newser
Altimmune Inc. stock volume spike explainedTrend Reversal & Accurate Entry/Exit Alerts - Newser
Top chart patterns to watch in Altimmune Inc.2025 Momentum Check & Weekly Breakout Watchlists - Newser
Quantitative breakdown of Altimmune Inc. recent moveSwing Trade & High Conviction Investment Ideas - Newser
Contact The Gross Law Firm by October 6, 2025 Deadline to Join Class Action Against Altimmune, Inc.(ALT) - PR Newswire
Join Class Action to Recover Losses from Altimmune, Inc. (ALT)Contact Levi & Korsinsky Before October 6, 2025 - Newsfile
Bragar Eagel & Squire, P.C. Reminds Investors of Novo, - GlobeNewswire
Altimmune to Participate in Upcoming Investor Conferences - The Manila Times
Late-Stage Biotech Altimmune Announces Triple Conference Presence: Wells Fargo, HC Wainwright, Morgan Stanley - Stock Titan
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming DeadlinesALT - WV News
Levi & Korsinsky Moves to SueWallSt for Altimmune, Inc. Investors That Lost Money - Stockhouse
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Altimmune, Inc. - GlobeNewswire
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Is Altimmune Inc. still worth holding after the dip2025 Growth vs Value & Low Risk Profit Maximizing Plans - Newser
Real time breakdown of Altimmune Inc. stock performanceJuly 2025 Recap & Free Technical Pattern Based Buy Signals - Newser
Class Action Filed Against Altimmune, Inc. (ALT)October 6, 2025 Deadline to Join – Contact Levi & Korsinsky - GlobeNewswire
Altimmune, Inc. Sued for Securities Law Violations - GlobeNewswire
Faruqi & Faruqi investigates potential claims against Altimmune, Inc. - AInvest
ALT STOCK: Robbins LLP Reminds ALT Stockholders of the Opportunity to Lead the Class Action Lawsuit Against Altimmune, Inc. - PR Newswire
Will Altimmune Inc. continue its uptrend2025 Breakouts & Breakdowns & Weekly High Potential Stock Alerts - Newser
Altimmune, Inc. (NASDAQ:ALT) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
Altimmune wins FDA fast track status for alcohol use disorder therapy - MSN
Will Altimmune Inc. stock recover after recent dropQuarterly Market Summary & Precise Trade Entry Recommendations - Newser
Altimmune Inc (ALT) Stock: A Comprehensive 52-Week Review - investchronicle.com
ALT SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Altimmune, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Altimmune (ALT) Gains FDA Fast Track for Alcohol Use Disorder Treatment - GuruFocus
Shareholders that lost money on Altimmune, Inc.(ALT) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - MarketScreener
Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD) - The Manila Times
Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD) | ALT Stock News - GuruFocus
Altimmune's Pemvidutide Receives FDA Fast Track Designation for Alcohol Use Disorder Treatment - Quiver Quantitative
大文字化:
|
ボリューム (24 時間):